Basics Allogene Therapeutics, Inc. IPO Date: October 8, 2018 Sector: Healthcare Industry: Biotech Market Cap: $339.34M Activated in VL: True Average Daily Range Avg Daily Range: $0.44 | 3.14% Avg Daily Range (30 D): $0.05 | 3.98% Avg Daily Range (90 D): $0.04 | 3.24% Institutional Daily Volume Avg Daily Volume: 1.57M Avg Daily Volume (30 D): 2.17M Avg Daily Volume (90 D): 2.87M Trade Size Avg Trade Size (Sh.): 146 Avg Trade Size (Sh.) (30 D): 291 Avg Trade Size (Sh.) (90 D): 364 Institutional Trades Total Inst.Trades: 2,903 Avg Inst. Trade: $1.85M Avg Inst. Trade (30 D): $.83M Avg Inst. Trade (90 D): $.84M Avg Inst. Trade Volume: .18M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.45M Avg Closing Trade (30 D): $1.12M Avg Closing Trade (90 D): $.97M Avg Closing Volume: 232.6K     News Nov 27, 2025 @ 4:00 PM U.S. CAR T-Cell Therapies Market Grows at 30.4% CA... Source: Towards Healthcare Jul 23, 2025 @ 1:26 PM High‑Growth Oncology Market Projected For U... Source: Prnewswire Jun 1, 2025 @ 2:45 PM Allogene Therapeutics Provides Updated Phase 1 Dat... Source: N/A Mar 5, 2025 @ 6:00 PM CAR T-cell Therapy Clinical Trial Pipeline Experie... Source: Delveinsight Dec 26, 2024 @ 4:26 PM Oncology in Focus: How Emerging Therapies Are Resh... Source: Prnewswire Financials   TTM Q3 2025 Q2 2025 Basic EPS $-.98 $-.19 Diluted EPS $-.98 $-.19 Revenue $ M $ M $ Gross Profit $ $ $ Net Income / Loss $ -212.02M $ -41.4M $ -50.94M Operating Income / Loss $ -227.4M $ -44.9M $ Cost of Revenue $ $ $ Net Cash Flow $ -13.42M $ $ PE Ratio